Evicita · Supplement evidence, graded and cited · Supplements · Lifestyle · Mechanisms · Lab tests · 中文

Sulforaphane

Sulforaphane (SFN) · also known as Broccoli seed extract, Sulforaphane, Glucoraphanin + Myrosinase

Sulforaphane is a classic inducer of the Nrf2 pathway, and randomized human trials have shown increases in its target enzyme NQO1. Human evidence for effects on HDAC and NF-κB is weaker, and those effects are brief and inconsistent.

Typical dose: 10–30 mg/day, expressed as free sulforaphane. If you choose a glucosinolate product (which needs active myrosinase), the 50–150 mg of glucosinolate on the label does not correspond to a fixed sulforaphane exposure. Go by the product instructions and the specific dosage form.
Absorption and forms: Free sulforaphane is unstable and degrades readily at room temperature. Glucoraphanin has to be converted to sulforaphane by active myrosinase, and the degree of conversion depends on enzyme activity, dosage form and individual gut microbiota. The milligrams of glucoraphanin on a label therefore cannot be converted into a fixed amount of actual exposure. Options include a product that contains active myrosinase, or a stabilized, microencapsulated free sulforaphane product.

Clinical uses and human evidence

Blood sugar and insulin resistance

Mixed resultsGrade B · Moderate evidence
Studies (2)
  1. Dwibedi 2025 · Nat Microbiol · RCT · n=89 — Effect of broccoli sprout extract and baseline gut microbiota on fasting blood glucose in prediabetes: a randomized, placebo-controlled trial
  2. Axelsson 2017 · Sci Transl Med · RCT · n=97 — Sulforaphane reduces hepatic glucose production and improves glucose control in patients with type 2 diabetes

Fatty liver and liver enzymes

Mixed resultsGrade C · Preliminary evidence
Studies (1)
  1. Kikuchi 2015 · World J Gastroenterol · RCT · n=52 — Sulforaphane-rich broccoli sprout extract improves hepatic abnormalities in male subjects

Mechanisms of action

Nrf2/ARE activation of endogenous antioxidant enzymes

★★★★★Mechanism evidence: grade APrimary target

Sulforaphane is a classic inducer of the Nrf2 pathway and can upregulate Nrf2 target genes. In one randomized double-blind human trial, NQO1 rose in nasal lavage cells of smokers. The size of the response varies with tissue, dose and formulation, and not everyone can be expected to respond equally.

References (2)
  1. Noah et al. 2014 · Randomized double-blind trial: after broccoli sprout intervention, NQO1 rose in nasal lavage cells of smokers
  2. Atwell et al. 2015 · Human crossover study: sulforaphane exposure was affected by plant form and myrosinase treatment

Epigenetic inhibition of histone deacetylases (HDACs)

★★☆☆☆Mechanism evidence: grade BSecondary target

Sulforaphane metabolites can inhibit HDAC in vitro. A small number of human studies found that HDAC activity in monocytes dropped briefly after eating broccoli sprouts. But the dose-response is unclear, as are the duration of the effect and its subtype selectivity.

References (2)
  1. Myzak et al. 2007 · Small human study: HDAC activity in peripheral blood mononuclear cells dropped briefly after eating broccoli sprouts
  2. Atwell et al. 2015 · Human crossover study: no clear HDAC dose-response was seen across different delivery methods

Inhibition of NF-κB / AP-1, the master switches of pro-inflammatory transcription

★★☆☆☆Mechanism evidence: grade CSecondary target

In experimental models, sulforaphane can reduce NF-κB binding to DNA. This may be related to cysteine modification of p65. The specific modification sites in humans have not been confirmed, and reliable pathway inhibition has not been directly measured after usual oral doses.

References (2)
  1. 2001 · Cell study: sulforaphane reduced NF-κB DNA binding, which may involve cysteine modification
  2. Nallasamy et al. 2014 · Mouse and cell study: vascular inflammation improved, and NF-κB signaling was suppressed in cells

Safety and drug interactions

Well tolerated at usual doses. High doses may cause gastrointestinal upset. In theory, thiocyanate from the breakdown of cruciferous glucosinolates could compete with iodine uptake by the thyroid, but no changes in thyroid function were seen in human trials. People with severe iodine deficiency and hypothyroidism may want to keep this in mind.
Open in the interactive app ›